Clinical trials: Epithelial Mesothelioma
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Pleura Mesothelioma
Diadem to Investigate the Activity and Safety of Durvalumab
Malignant pleural mesothelioma (MPM) is a cancer with high mortality rate and few therapeutic options.essentially all patients usually progress and die subsequently to a first line therapyl.
- Trial name
- Diadem (NCT04115111)
- Testing
- Durvalumab
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer
CART-meso in Mesothelin Expressing Cancers
Phase I study to establish safety and feasibility of intravenously administered lentiviral transduced CART-meso cells administered with and without cyclophosphamide in a 3+3 dose escalation design in patients with metastatic…
- Conditions
- Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer, Malignant Epithelial Pleural Mesothelioma
- Trial name
- NCT02159716
- Testing
- CART-meso
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pennsylvania
Malignant Pleural Mesothelioma, Advanced
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural…
- Trial name
- NCT07885319
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- 3 sites in China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
Mesothelioma
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab in combination with bevacizumab and chemotherapy as first-line treatment for…
- Trial name
- NCT07514793
- Testing
- Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Peritoneal Carcinomatosis
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
Phase Ib trial including investigating the combination of nab-paclitaxel and cisplatin in patients diagnosed with peritoneal carcinomatosis related to pancreatic, oeso-gastric, ovarian cancer or primitive peritoneal mesothelioma.
- Trial name
- Nab-PIPAC (NCT04000906)
- Testing
- Nab paclitaxel, Cisplatin
- Where
- 2 sites in Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Geneva
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Mesothelioma, Recurrent Malignant Mesothelioma
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood…
- Conditions
- Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma
- Trial name
- NCT00107432
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Mesothelioma
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Background: Mesothelioma is cancer of the tissue that lines some organs. A new drug, LMB-100, may bind to a protein on mesothelioma tumors and kill cancer cells.
- Trial name
- NCT03436732
- Testing
- LMB-100, SEL-110
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma
DENdritic Cell Immunotherapy for Mesothelioma
This study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to BSC…
- Trial name
- DENIM (NCT03610360)
- Testing
- MesoPher
- Where
- 6 sites in Belgium, France and 3 more
- Volunteers
- 176 people
- Sponsor
- Amphera BV
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Malignant Mesothelioma
S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003723
- Testing
- gemcitabine hydrochloride
- Where
- 84 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration
Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura.
- Conditions
- Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma Breast Stage IV, Ovarian Cancer
- Trial name
- PITHAC (NCT06281860)
- Testing
- Cisplatine Teva®
- Where
- Switzerland
- Volunteers
- 39 people
- Sponsor
- Dr Jean Yannis PERENTES
Breast Cancer, Colorectal Cancer
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00703638
- Testing
- cisplatin, pemetrexed disodium, sorafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Solid Tumors, Adult, Solid Tumor
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally…
- Conditions
- Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE)
- Trial name
- NCT05228015
- Testing
- IK-930, Osimertinib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- Ikena Oncology
Lung Adenocarcinoma, Ovarian Cancer
CAR T Cells in Mesothelin Expressing Cancers
Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
- Conditions
- Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03054298
- Testing
- huCART-meso cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Pennsylvania
Mesothelioma
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin…
- Trial name
- MAGIC-AKI (NCT05730816)
- Testing
- Magnesium sulfate, Normal Saline
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Brigham and Women's Hospital
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid…
- Conditions
- Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
- Trial name
- NCT07713732
- Testing
- TLN-499, Venetoclax
- Where
- 3 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Treeline Biosciences, Inc.
Pleural Mesothelioma
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care.
- Trial name
- TIGER Meso (NCT05538806)
- Testing
- TTFields
- Where
- 23 sites in Germany, Italy and 1 more
- Volunteers
- 198 people
- Sponsor
- NovoCure Ltd.